The drug major announced that one of its wholly owned subsidiaries has received final approval from USFDA for its abbreviated new drug application (ANDA) for generic lenalidomide capsules, 5mg, 10mg, 15mg, 25mg and tentative approval for 2.5mg, 20mg.
